Genomic test to establish the recurrence risk in women with breast cancer.
Using NanoString nCounter® Dx technology and the PAM50 gene signature analysis algorithm, it is the only test that can classify the intrinsic subtype of the breast tumour, as well as establishing a risk category based on the probability of recurrence (POR) at 10 years. To do so, it takes into account clinical variables such as tumour size and the patient’s nodal status, as well as the molecular information.
La Prosigna's reliability is guaranteed by:
- Clinical trials in the USA and Spain, which demonstrate that it is a reproducible, accurate and robust test.
- FDA-approved genomic test with CE marking.
¿When is it indicated?
As a prognostic indicator in postmenopausal women with breast cancer who have undergone a mastectomy or breast-conserving therapy, as well as the usual locoregional treatment, in the following conditions:
- Patients with stage I and II hormone receptor-positive lymph node-negative tumours, to be treated with adjuvant endocrine therapy
- Patients with stage II and IIIA hormone receptor-positive and lymph node-positive tumours to be treated with adjuvant endocrine therapy.
Turnaround time: 15 working days from receipt of the sample.
Please remember to attach the Application Form and Informed Consent Form to the sample, which you will find on the right.